Heard on the Hill: GRADES ARE IN

WASHINGTON REPORTER

Unleash Prosperity Now is rolling out a new scorecard, obtained exclusively by the Washington Reporter, that ranks “the US, UK, France, Germany, and Japan on drug pricing, patient access, and whether each has answered Trump’s call to end foreign freeloading on US drug innovation.” The project is called Most Favored Patient (MFP). Stephen Moore, Steve Forbes, Tomas Philipson, and Phil Kerpen are all involved in the new project. America is the clear leader in the ratings. “Foreign freeloading means fewer new treatments and cures are developed, and the ones we do get cost more than they should for American patients,” Kerpen explained. “President Trump is working to hold these nations accountable, and he should continue pushing hard in trade negotiations to stop the free-riding on U.S. pharmaceutical innovation.”

Read more here.